歌礼制药-B涨超8% ASC50治疗银屑病新药临床试验申请已获FDA批准

智通财经
27 May

歌礼制药-b(01672)涨超8%,截至发稿,涨7.92%,报6.95港元,成交额2205.46万港元。消息面上,歌礼制药近日宣布其治疗轻中度斑块状银屑病的ASC50的I期新药临床试验申请(IND)已于近期获美国食品药品监督管理局(FDA)批准。ASC50为歌礼自主研发的口服小分子白细胞介素-17(IL-17)靶向抑制剂,该靶点在银屑病等多种自身免疫及炎症性疾病领域已获充分的生物学验证并具备成熟...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10